Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* HCV RNA ≥ 10\^4 IU/mL at screening~* HCV genotype 1, 2, 3, 4, 5, 6~* Cirrhosis determination, a fibroscan or liver biopsy may be required~* HIV-1 infection~* Use of protocol specified method(s) of contraception~* Screening laboratory values within defined thresholds~Key Exclusion Criteria:~* Clinically-significant illness (other than HCV or HIV) or any other major medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol~* Current or prior history of clinical hepatic decompensation, hepatocellular carcinoma (HCC) or other malignancy (with the exception of certain resolved skin cancers)~* Screening ECG with clinically significant abnormalities~* Pregnant or nursing female or male with pregnant female partner~* Infection with hepatitis B virus (HBV)~* Use of any prohibited concomitant medications as described in the protocol~* Chronic use of systemically administered immunosuppressive agents~NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL (Type: EXPERIMENTAL): Participants will receive SOF/VEL for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).